Susan C. Modesitt, MD, FACOG, FACS, discusses the role of PARP inhibitors in the treatment of patients with ovarian cancer.
Susan C. Modesitt, MD, FACS, FACOG
Advertisement
Articles by Susan C. Modesitt, MD, FACS, FACOG
Emerging data have confirmed that ovarian cancer is a much more heterogeneous disease than previously recognized.
Advertisement
Latest Updated Articles
Dr Modesitt on Shared Decision-Making When Choosing PARP Inhibitors in Ovarian CancerPublished: February 29th 2024 | Updated:
Inheritance Matters: The Race to Prevent New Ovarian Cancer CasesPublished: January 31st 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5